{
    "clinical_study": {
        "@rank": "13340", 
        "arm_group": {
            "arm_group_label": "SOL, single arm", 
            "arm_group_type": "Experimental", 
            "description": "S-1 combined with leucovorin and oxaliplatin"
        }, 
        "brief_summary": {
            "textblock": "In China, S-1 is an novel oral fluoropyrimidine with demonstrated high efficacy on\n      gastrointestinal cancer. The new regimen with oxaliplatin and leucovorin is expected to\n      achieve more encouraging efficacy on gastric cancer. This study is aimed to evaluate the\n      feasibility of the SOL regimen on efficacy and tolerability on Chinese patients with\n      advanced gastric cancer."
        }, 
        "brief_title": "Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age over 18 years old\n\n          -  Histologically or cytologically documented gastric adenocarcinoma\n\n          -  Performance status (ECOG scale): 0-2\n\n          -  Life expectancy \u2265 3 months\n\n          -  No previous treatment(including: radiotherapy,chemotherapy and immunotherapy)\n\n          -  Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive\n             immunotherapy) for adjuvant or neoadjuvant treatment for non-metastatic (M0) disease\n             has been completed within 6 months prior to initiation of study treatment.\n\n          -  WIth Measurable Target lesion\n\n          -  Patients should sign a written informed consent before study entry\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity to fluoropyrimidines, S-1, oxaliplatin or the ingredients\n             product\n\n          -  Inadequate hematopoietic function: WBC\u22665,000/mm3; ANC\u22662,000/mm3; Platelet\u2266100,000/mm3\n\n          -  Inadequate organ function which is defined as below:\n\n        Total bilirubin >2 pper limit of normal range (ULN); ALT / AST > 2.5 upper limit of normal\n        range (ULN) (>5.0 x ULN if hepatic metastasis); serum creatinine > 2 upper limit of normal\n        range (ULN);\n\n          -  Symptomatic peripheral neuropathy \u2265 NCI CTC AE grade 1;\n\n          -  Receiving a concomitant treatment with other fluoropyrimidines or  fluorocytosine;\n\n          -  Pregnancy or lactation women, or women with suspected pregnancy or men unless using a\n             reliable and appropriate contraceptive method;\n\n          -  Mental status is not fit for chemotherapy therapy presence of serious concomitant\n             illness which might be aggravated by study medication;\n\n          -  History of ventricular arrhythmia or congestive heart failure;\n\n          -  Active cardiac disease e.g. decompensate myocardial infarction within the 6-month\n             period preceding entry into the study;\n\n          -  Significant co-morbid medical conditions, including, but not limited to, Chronic\n             obstructive pulmonary disease, interstitial pneumonia ,pulmonary heart failure, renal\n             failure, hepatic failure, haemorrhagic peptic ulcer, mechanical, paralytic or poor\n             control diabetes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "49", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980407", 
            "org_study_id": "JPCH1301", 
            "secondary_id": "TOTMS1311"
        }, 
        "intervention": {
            "arm_group_label": "SOL, single arm", 
            "description": "S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14\uff1b Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.", 
            "intervention_name": "S-1, leucovorin, oxaliplatin", 
            "intervention_type": "Drug", 
            "other_name": [
                "S-1 (20mg):Taiho Pharmaceutical Co., Ltd.\uff1b", 
                "formyltetrahydrofolate (15mg)", 
                "L-OHP (50mg)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Formyltetrahydrofolates", 
                "Leucovorin", 
                "Levoleucovorin", 
                "Oxaliplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "S-1", 
            "Oxaliplatin", 
            "Leucovorin", 
            "Gastric Cancer"
        ], 
        "lastchanged_date": "November 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Changchun", 
                    "country": "China", 
                    "state": "Jilin"
                }, 
                "name": "Jilin Provincial Tumor Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Safety and Efficacy Study of S-1, Oxaliplatin, and Leucovorin (SOL) in Patients With Advanced Gastric Cancer", 
        "overall_contact": {
            "email": "JPCH2013@163.com", 
            "last_name": "Yue Zhang, MD, Ph.D", 
            "phone": "+86-0431-85872596"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the objective response rate followed by RECIST 1.1.", 
            "measure": "Response rate", 
            "safety_issue": "No", 
            "time_frame": "6-8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980407"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jilin Provincial Tumor Hospital", 
            "investigator_full_name": "Zhang Yue", 
            "investigator_title": "Head of Department of Integrated Traditional Chinese and Western Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, The number of Participants with adverse events will be recorded at each treatment visit.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 year"
            }, 
            {
                "description": "Tumor assessment will be performed every 3 cycles (9 weeks) from the start of treatment until progression or as for the metastatic site developed during the study (including clinical suspicion). In order to confirm objective tumor response, additional confirmatory scan should be obtained at least 4 weeks following the first radiological evidence of tumor response.", 
                "measure": "Progress free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 9 weeks"
            }, 
            {
                "description": "To Assess disease control rate (DCR) as defined CR + PR + SD assessed by RECIST criteria", 
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "up to 9 weeks"
            }
        ], 
        "source": "Jilin Provincial Tumor Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jilin Provincial Tumor Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}